Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ompetition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development

$1,002

$862

$4,527

$3,552  General and administrative

1,380

2,510

5,372

6,857  Total operating expenses

2,382

3,372

9,899

10,409Total operating loss

(2,382)

(3,372)

(9,899)

(10,409)Other income and (expense):  Interest income

6

4

24

18  Change in fair value of warrant liabilities

-

-

-

(524)  Other income

-

-

200

-Total other income (expense)

6

4

224

(506)Net loss

$(2,376)

$(3,368)

$(9,675)

$(10,915)Preferred stock dividends and accretion costs

(332)

(350)

(1,206)

(1,798)Net loss applicable to common stock

$(2,708)

$(3,718)

$(10,881)

$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share

15,966

12,846

15,131

11,986 Condensed Consolidated Balance She
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015  US-Australian drug discovery and development company, ... that it will present at the Brain Tumor Biotech Summit ... on May 29, 2015. The venue is the Lennox Hill ... . The Brain Tumor Biotech Summit brings ... industry and the investment community to promote innovative new therapies ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 The ... evaluating the impact of regulation on medical innovation, has ... Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ... MI3 Alert pertains to new FDA (Food ... proposal for accelerating the approval of certain medical devices. ...
(Date:5/26/2015)... OTTAWA, Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, ... has signed a formal partnership with the ... Ottawa Centre for Extreme and Quantum Photonics. The center ... in the field of photonics, and will be only ... Arthurs, CEO of SPIE, the international society for ...
(Date:5/26/2015)... May 26, 2015 WORMS, GERMANY ... & Co. (NYSE: GRA) announces that its manufacturing ... practice (GMP) certification from EXCiPACT™, an independent organization ... excipients. , All three Grace facilities ... grade excipient silica gels have now received GMP ...
Breaking Biology Technology:Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... -- Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... Christian Itin, will participate in a panel discussion titled ... Markets Healthcare Conference on December 10, 2008. The ...
... based on the products of newborn fibroblasts, will be featured in ... 21st Century Breakthroughs for Biomedical Research series. , ... ... medicine company developing solutions based on the products of newborn fibroblasts, ...
... closures observed in PRECiSE 2 trial under maintenance therapy with ... , HOLLYWOOD, Fla., Dec. 5 Data ... Diseases 2008, the Crohn,s & Colitis Foundation,s Clinical & Research ... severe Crohn,s disease patients who had open fistulas at baseline ...
Cached Biology Technology:Micromet to Present at the RBC Capital Markets Healthcare Conference 2Micromet to Present at the RBC Capital Markets Healthcare Conference 3Micromet to Present at the RBC Capital Markets Healthcare Conference 4Histogen Featured on Economic Report Television Series 2New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 2New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 3New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 4New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 5New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 6New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 7New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 8New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizing Disease 9
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... machine can draw your blood, screen it for genetic mutations ... a drug tailor-made for your DNA. That hypothetical drug ... have accumulated over time that can lead to the formation ... Health has tapped Viterbi professor Andrea Armani to develop a ...
... award up to $64 million over five years to ... that have the potential for extraordinary impact. ... allows investigators to sidestep conventional stumbling blocks they often ... as the need for preliminary data or a restriction ...
... Institutes of Health (NIH) has awarded $11.5 million to ... Institute of Technology (Caltech) for the creation of a ... centercalled the Center for the X-ray Structure Determination of ... by the NIH to "solve the structures of these ...
Cached Biology News:Fighting cancers by tagging their triggers 2NIH awards $11.5 million for new Caltech-led membrane-protein center 2
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: